Evidence map›Paper›PMID 36214559›Full record

ArticlemBio2022

Solanimycin: Biosynthesis and Distribution of a New Antifungal Antibiotic Regulated by Two Quorum-Sensing Systems.

Miguel A Matilla, Rita E Monson, Annabel Murphy, Muriel Schicketanz, Alison Rawlinson, Caia Duncan, Juan Mata, Finian Leeper, George P C Salmond

Open access · goldAbstract read
In one paragraph

Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Dissimilar gene repertoires ofFrontiers in plant science · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Miguel A Matilla *Department of Biochemistry, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.
Rita E Monson *Department of Biochemistry, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.
Annabel MurphyYusuf Hamied Department of Chemistry, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.
Muriel SchicketanzDepartment of Biochemistry, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.
Alison RawlinsonDepartment of Biochemistry, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.
Caia DuncanDepartment of Biochemistry, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.
Juan MataDepartment of Biochemistry, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.
Finian LeeperYusuf Hamied Department of Chemistry, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.
George P C SalmondDepartment of Biochemistry, University of Cambridgegrid.5335.0, Cambridge, United Kingdom.
University of Cambridge · GBConsejo Superior de Investigaciones Científicas · ES

Funding

Biotechnology and Biological Sciences Research Council BB/N008081/1
6 · The paper itself

Abstract

The increasing emergence of drug-resistant fungal infections has necessitated a search for new compounds capable of combating fungal pathogens of plants, animals, and humans. Microorganisms represent the main source of antibiotics with applicability in agriculture and in the clinic, but many aspects of their metabolic potential remain to be explored. This report describes the discovery and characterization of a new antifungal compound, solanimycin, produced by a hybrid polyketide/nonribosomal peptide (PKS/NRPS) system in Dickeya solani, the enterobacterial pathogen of potato. Solanimycin was active against a broad range of plant-pathogenic fungi of global economic concern and the human pathogen Candida albicans. The genomic cluster responsible for solanimycin production was defined and analyzed to identify the corresponding biosynthetic proteins, which include four multimodular PKS/NRPS proteins and several tailoring enzymes. Antifungal production in D. solani was enhanced in response to experimental conditions found in infected potato tubers and high-density fungal cultures. Solanimycin biosynthesis was cell density dependent in D. solani and was controlled by both the ExpIR acyl-homoserine lactone and Vfm quorum-sensing systems of the bacterial phytopathogen. The expression of the solanimycin cluster was also regulated at the post-transcriptional level, with the regulator RsmA playing a major role. The solanimycin biosynthetic cluster was conserved across phylogenetically distant bacterial genera, and multiple pieces of evidence support that the corresponding gene clusters were acquired by horizontal gene transfer. Given its potent broad-range antifungal properties, this study suggests that solanimycin and related molecules may have potential utility for agricultural and clinical exploitation.

Indexed as

Antifungal AgentsBacteriaAnimalsAnti-Bacterial AgentsEnterobacteriaceaeFungiHumansPhylogenyAnti-Bacterial AgentsAntifungal Agentsacyl-homoserine lactoneagriculture and global food securityantibioticsantifungal agentsDickeya solanigene regulationhorizontal gene transferhybrid polyketide/nonribosomal peptidephytopathogenspost-transcriptional control mechanismsquorum sensingsecondary metabolism

Identifiers

PMID36214559
PMCPMC9765074
OpenAlexW4303986696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.